Clinical trials show significant weight regain when GLP-1 medications are stopped. Here’s what the data says, why it happens, and what patients can do about it.
One of the most important — and most underreported — findings in GLP-1 research is what happens when patients stop taking the medication. The STEP 4 trial, which followed patients who had lost weight on semaglutide and then switched to placebo, found that participants regained an average of two-thirds of their lost weight within one year of stopping.
STEP 4 trial: Patients who stopped semaglutide after 20 weeks regained an average of 11.6% of body weight within 48 weeks, compared to continued loss of 7.9% in those who stayed on the medication.
Why Regain Happens
Weight regain after stopping GLP-1 medications is not a failure of the patient — it is the expected biological response. The medication was suppressing appetite and slowing gastric emptying. When it’s removed, those effects disappear. The underlying biology that was driving weight gain — the dysregulated appetite signaling, the elevated set point — reasserts itself.
This is analogous to stopping antihypertensive medication: blood pressure returns to its previous level because the underlying condition hasn’t been cured, only managed. Obesity is a chronic disease, and GLP-1 medications are a chronic disease management tool.
What Patients Can Do
The research on weight regain has important implications for how patients and clinicians should think about GLP-1 therapy. Several strategies can help minimize regain if medication is stopped or reduced:
- Build durable behavioral habits during the medication period — the habits formed while appetite is suppressed are easier to maintain
- Prioritize protein intake and resistance training to preserve lean muscle mass during weight loss
- Work with your clinical team on a gradual dose reduction rather than abrupt discontinuation
- Have a maintenance plan in place before stopping — not after regain begins
- Consider long-term, lower-dose maintenance therapy if stopping entirely is not feasible
The SCAPS Approach to Medication Transitions
At SCAPS, we discuss medication duration and transition planning from the beginning of treatment — not as an afterthought. The education curriculum is specifically designed to build the behavioral foundation that supports long-term maintenance, whether patients continue medication or not.
For patients who need to stop medication for cost, side effect, or other reasons, we develop individualized transition plans that include nutritional strategy, behavioral check-ins, and monitoring for early signs of regain. The goal is to give every patient the best possible chance of maintaining their results.